The NM_000156.6:c.505T>A variant in GAMT is a missense variant predicted to cause substitution of a cysteine by tyrosine at amino acid 169 (p.Cys169Tyr). At least 4 unrelated probands and one sibling were found to be homozygous for the variant (PMID: 15651030, 2323426424415674, 24268530, 32606525) (max 2 x 0.5, PM3). Three individuals with the variant had elevated guanidinoacetate in plasma and/or urine); in addition, one individual showed absent creatine peak on brain MRS; another had deficient (<5% wild-type) GAMT activity in lymphoblasts ( PMID: 15651030, 24268530, 24415674). Two sibs had absent creatine peak on brain MRS (PMID: 32606525) (PP4_Strong). The highest population minor allele frequency in gnomAD v4.1.0. is 0.0000333 (2/60014 alleles) in the Admixed American population, which is lower than the ClinGen CCDS VCEP’s threshold for PM2_Supporting (<0.0004), meeting this criterion (PM2_Supporting). Expression of the variant in GAMT-deficient fibroblasts resulted in <5% wild type GAMT activity indicating that this variant may impact protein function (PMID: 24415674)(PS3_Supporting). The computational predictor REVEL gives a score of 0.754 which is in the range of 0.644-0.773, evidence that correlates with impact to GAMT function at the supporting level (PP3). There is a ClinVar entry for this variant (Variation ID: 8304). In summary, this variant meets the criteria to be classified as likely pathogenic for GAMT deficiency based on the GAMT-specific ACMG/AMP criteria applied, as specified by the ClinGen Cerebral Creatine Deficiency Syndromes Variant Curation Expert Panel (Specifications Version 2.0.0): PP4_Strong, PM3, PP3, PS3_Supporting, PM2_Supporting (Classification approved by the ClinGen Cerebral Creatine Deficiency Syndromes Variant Curation Expert Panel on October 16, 2025)